Eckert & Ziegler stock: Pentixapharm extends bond terms
Published on 11/19/2026 at 17:12 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSFinancing terms shift at Pentixapharm
- Pentixapharm extended its convertible bond maturity to 2030 while retaining Eckert & Ziegler as sole bondholder.
- The coupon will rise to 6.00 percent from January 2027, and the agreement has a stated value of EUR 3.7 million.
- The arrangement could affect future funding flexibility, conditional capital and conversion rights at Pentixapharm.
Pentixapharm Holding AG entered into an amendment agreement with Eckert & Ziegler SE on November 12, 2026, covering a EUR 18.5 million convertible bond. The arrangement keeps Eckert & Ziegler as sole bondholder and extends the bond's maturity from December 31, 2027, to December 31, 2030, according to the Pentixapharm release published by PR Newswire.
Longer maturity, higher coupon
The amendment allows Pentixapharm to draw the issue price of 27 bonds not yet issued, with an aggregate principal amount of EUR 13.5 million, until June 30, 2030. Pentixapharm may also redeem the bond early at principal plus accrued interest.
In return, the interest rate will rise from 4.00 percent to 6.00 percent annually on January 1, 2027. Repayment of the EUR 5.0 million principal already issued is deferred by three years, while the conversion right may generally be exercised at any time during the extended term.
Implications for capital structure
The parties put the total value of the amendment at approximately EUR 3.7 million, based on the potential additional interest expense assuming all 37 bonds are issued. The companies also agreed on equal security treatment for the convertible bond alongside other comparable capital-market liabilities.
Pentixapharm said its management and supervisory boards approved the changes. The company plans to propose an increase in conditional capital at its 2027 annual general meeting to cover conversion rights; until then, conversion rights exceeding existing conditional capital may be serviced with treasury shares, authorized capital or cash settlement.
Eckert & Ziegler stock traded at EUR 14.79 on Lang & Schwarz at 17:03 CET on Thursday, November 19, 2026, 1.27 percent below the Xetra close of Wednesday, November 18, 2026, at EUR 14.98.
Eckert & Ziegler at a glance
- Company: Eckert & Ziegler SE
- ISIN: DE0005659700
- Ticker: EUZ.DE
- Trading venue: Lang & Schwarz
- Quote: EUR 14.79 at 17:03 CET on November 19, 2026
- Daily comparison: 1.27 percent below the Xetra close of November 18, 2026
- Xetra close: EUR 14.98 on November 18, 2026
German equities remain the relevant market setting for investors following the company; see Current market reports.
